Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Overview
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Companies Involved in Therapeutics Development
Anelixis Therapeutics LLC
Bristol-Myers Squibb Co
eTheR Immunotherapies NV
Memgen LLC
paJen Pharma Inc
Sanofi
Shattuck Labs Inc
TILT Biotherapeutics Ltd
Tonix Pharmaceuticals Holding Corp
UCB SA
Viela Bio Inc
XL-protein GmbH
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drug Profiles
AT-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dapirolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate CD40LG for Genetic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD40 Ligand for Malignt Melanoma and Bladder Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISF-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
letolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NJA-730 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-115154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-172154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-1500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40L and GM-CSF for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIB-4920 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Dormant Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Discontinued Products
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Viela Bio announces initiation of phase 2b trial of VIB4920 in Sjogren’s Syndrome
Nov 08, 2019: UCB Presents new data on investigatiol molecule Dapirolizumab Pegol at the 2019 American College of Rheumatology and the Association of Rheumatology Professiols (ACR/ARP) Annual Meeting
Aug 21, 2019: Tonix Pharmaceuticals and Massachusetts General Hospital enter into research collaboration to develop Tonixs third generation anti-CD154 monoclol antibody, TNX-1500, for the treatment and prevention of organ transplant rejection
Jun 01, 2019: Safety and immune stimulation data from an intranodal delivery of TriMix mR, in the adjuvant melanoma study E011-MEL
Mar 04, 2019: eTheR immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma
Nov 28, 2018: Augie’s Quest reports first subject successfully enrolled in AT-1501 phase 1 study, a first-of-its-kind, promising treatment for ALS
Nov 15, 2018: paJen Pharma announces first patient dosed in phase 1 first-in-human clinical trial of novel R interference (Ri) therapeutic
Oct 23, 2018: UCB and Biogen announce topline results from a phase 2b study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
Oct 19, 2018: Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920 at the 2018 ACR/ARHP Annual Meeting
Oct 08, 2018: eTheR Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mR Cancer Immunotherapies
May 24, 2018: eTheR Enrols First Patient in High Dose Cohort of Phase 1b study of TriMix mR-based Cancer Specific Immunotherapy (ECI-006) in Melanoma
Mar 19, 2018: eTheR completes enrolment of low dose cohort for Phase 1b study of TriMix mR-based cancer specific immunotherapy (ECI-006) in melanoma
Jun 30, 2017: ether Advances in-vivo MR Cancer Immunotherapy Into First Oncology Clinical Studies
Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)
Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combition with Checkpoint Inhibitors in a Model of Metastatic Melanoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Anelixis Therapeutics LLC, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by eTheRNA Immunotherapies NV, H2 2019
Pipeline by Memgen LLC, H2 2019
Pipeline by NapaJen Pharma Inc, H2 2019
Pipeline by Sanofi, H2 2019
Pipeline by Shattuck Labs Inc, H2 2019
Pipeline by TILT Biotherapeutics Ltd, H2 2019
Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2019
Pipeline by UCB SA, H2 2019
Pipeline by Viela Bio Inc, H2 2019
Pipeline by XL-protein GmbH, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019